marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Intellia Therapeutics Balance Sheet 2011-2024 | NTLA
Annual Balance Sheet Intellia Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-111 M | -393 M | -49.4 M | - | - | -58.9 M | -341 M | -273 M | -75.8 M | -9.84 M | - | - | - |
Long Term Debt |
96.7 M | 114 M | 64.9 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
18.6 M | 16.7 M | 9.11 M | 5.7 M | 5.74 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 28.8 M | 44.3 M | 58.4 M | 4.09 M | 773 K | - | - | - |
Total Current Liabilities |
115 M | 127 M | 126 M | 64.3 M | 35.6 M | 40.6 M | 31.4 M | 30.7 M | - | - | - | - | - |
Total Liabilities |
251 M | 285 M | - | - | - | 69.4 M | 75.6 M | 89.1 M | 14.8 M | 3.13 M | - | - | - |
Deferred Revenue |
22.1 M | 43.8 M | 63.8 M | 22.5 M | 12.7 M | 27.1 M | 21.2 M | 20.2 M | 6.55 M | - | - | - | - |
Retained Earnings |
-1.66 B | -1.18 B | -703 M | -435 M | -301 M | -201 M | -121 M | -53.6 M | -21.9 M | -9.54 M | - | - | - |
Total Assets |
1.3 B | 1.52 B | 1.29 B | 676 M | 334 M | 347 M | 376 M | 299 M | 82.1 M | 10.7 M | - | - | - |
Cash and Cash Equivalents |
227 M | 524 M | 123 M | 160 M | 57.2 M | 58.9 M | 341 M | 273 M | 75.8 M | 9.84 M | - | - | - |
Book Value |
1.05 B | 1.24 B | 1.29 B | 676 M | 334 M | 278 M | 301 M | 210 M | 67.4 M | 7.57 M | - | - | - |
Total Shareholders Equity |
1.05 B | 1.24 B | 1.04 B | 527 M | 270 M | 278 M | 301 M | 210 M | -21.2 M | 7.57 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Intellia Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
82.4 M | 87.3 M | 92.1 M | 96.7 M | 101 M | 106 M | 110 M | 114 M | 84.1 M | - | 62.5 M | 64.9 M | 67.3 M | 63.3 M | 64.5 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
211 M | 220 M | 223 M | 251 M | 206 M | - | - | 285 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
22.2 M | 22.2 M | 22.2 M | 22.1 M | 13.3 M | 21.9 M | 35.3 M | 43.8 M | 54.8 M | - | 63.8 M | 63.8 M | 56.8 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 27.1 M | 27.1 M | 15.7 M | 17.1 M | 21.2 M | 17.7 M | 18.8 M | 21.2 M | 20.2 M | 20.2 M | 20.2 M | 20.2 M | 6.55 M | 6.55 M | 6.55 M | 6.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.05 B | -1.91 B | -1.77 B | -1.66 B | -1.53 B | -1.4 B | -1.28 B | -1.18 B | -1.06 B | - | -850 M | -703 M | -622 M | -550 M | -481 M | -435 M | -435 M | -435 M | -435 M | -301 M | -301 M | -301 M | -301 M | -201 M | -201 M | -201 M | -201 M | -121 M | -121 M | -121 M | -121 M | -53.6 M | -53.6 M | -53.6 M | -53.6 M | -21.9 M | -21.9 M | -21.9 M | -21.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.17 B | 1.19 B | 1.26 B | 1.3 B | 1.24 B | 1.32 B | 1.42 B | 1.52 B | 1.08 B | - | 1.2 B | 1.29 B | 1.33 B | 672 M | 717 M | 676 M | 676 M | 676 M | 676 M | 334 M | 334 M | 334 M | 334 M | 347 M | 347 M | 347 M | 347 M | 376 M | 376 M | 376 M | 376 M | 299 M | 299 M | 299 M | 299 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
120 M | 131 M | 172 M | 227 M | 168 M | 172 M | 294 M | 524 M | 141 M | 148 M | 133 M | 123 M | 335 M | 130 M | 142 M | 160 M | 160 M | 160 M | 160 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 341 M | 341 M | 341 M | 341 M | 273 M | 273 M | 273 M | 273 M | 75.8 M | 75.8 M | 75.8 M | 75.8 M | 9.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
963 M | 971 M | 1.04 B | 1.05 B | 1.04 B | 1.32 B | 1.42 B | 1.24 B | 1.08 B | - | 1.2 B | 1.29 B | 1.33 B | 672 M | 717 M | 676 M | 676 M | 676 M | 676 M | 334 M | 334 M | 334 M | 334 M | 347 M | 347 M | 347 M | 347 M | 376 M | 376 M | 376 M | 376 M | 299 M | 299 M | 299 M | 299 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
963 M | 971 M | 1.04 B | 1.05 B | 1.04 B | 1.1 B | 1.19 B | 1.24 B | 825 M | 881 M | 954 M | 1.04 B | 1.11 B | 495 M | 546 M | 527 M | 527 M | 527 M | 527 M | 270 M | 270 M | 270 M | 270 M | 278 M | 278 M | 278 M | 278 M | 301 M | 301 M | 301 M | 301 M | 210 M | 210 M | 210 M | 210 M | -21.2 M | -21.2 M | -21.2 M | -21.2 M | 7.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency